updated 6/21/2010 10:14:43 AM ET 2010-06-21T14:14:43

The Supreme Court is allowing a new trial in the case of a woman who got breast cancer after taking hormone replacement therapy and is seeking punitive damages against Wyeth Pharmaceuticals.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The justices on Monday rejected Wyeth's attempt to block the trial because it is to be limited to punitive damages. Wyeth also wanted the high court to throw out $2.75 million compensatory damages that the woman, Donna Scroggin of Little Rock, Ark., won after suing Wyeth and Upjohn Co., another drugmaker. Both companies now are owned by Pfizer Inc.

A jury also awarded Scroggin $27 million in punitive damages after concluding that Wyeth inadequately warned her that its drugs Premarin and Prempro carried an increased risk of breast cancer.

A federal judge struck down the punitive damages award, saying certain testimony from former Food and Drug Administration official Dr. Suzanne Parisian, who was the plaintiff's regulatory expert, shouldn't have been allowed at trial.

The 8th U.S. Circuit Court of Appeals in St. Louis ordered the partial retrial, limited to punitive damages.

Chief Justice John Roberts, who owns Pfizer stock, did not take part in the consideration of the case.

The case is Wyeth v. Scroggin, 09-1123.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments